Moderna, Inc. (NASDAQ:MRNA) Stake Increased by MML Investors Services LLC

MML Investors Services LLC lifted its holdings in Moderna, Inc. (NASDAQ:MRNA) by 21.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 33,895 shares of the company’s stock after buying an additional 6,018 shares during the period. MML Investors Services LLC’s holdings in Moderna were worth $2,265,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Orion Portfolio Solutions LLC grew its stake in Moderna by 65.1% during the 3rd quarter. Orion Portfolio Solutions LLC now owns 3,661 shares of the company’s stock valued at $245,000 after acquiring an additional 1,443 shares in the last quarter. XTX Topco Ltd grew its position in Moderna by 889.4% during the third quarter. XTX Topco Ltd now owns 28,256 shares of the company’s stock valued at $1,888,000 after purchasing an additional 25,400 shares in the last quarter. National Bank of Canada FI grew its position in Moderna by 62.8% during the third quarter. National Bank of Canada FI now owns 235,266 shares of the company’s stock valued at $15,723,000 after purchasing an additional 90,739 shares in the last quarter. iA Global Asset Management Inc. increased its stake in Moderna by 4.1% in the 3rd quarter. iA Global Asset Management Inc. now owns 39,184 shares of the company’s stock valued at $2,619,000 after buying an additional 1,536 shares during the period. Finally, Kovitz Investment Group Partners LLC lifted its position in Moderna by 3.6% in the 3rd quarter. Kovitz Investment Group Partners LLC now owns 48,763 shares of the company’s stock worth $3,125,000 after buying an additional 1,684 shares in the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Insider Activity at Moderna

In related news, insider Shannon Thyme Klinger sold 1,418 shares of the company’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the transaction, the insider now directly owns 19,717 shares in the company, valued at approximately $843,690.43. This represents a 6.71 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO James M. Mock sold 715 shares of Moderna stock in a transaction on Monday, October 7th. The stock was sold at an average price of $60.12, for a total transaction of $42,985.80. Following the sale, the chief financial officer now owns 9,505 shares in the company, valued at $571,440.60. This represents a 7.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 3,379 shares of company stock worth $158,195. Company insiders own 15.70% of the company’s stock.

Moderna Stock Down 2.3 %

Shares of MRNA stock opened at $41.83 on Monday. Moderna, Inc. has a 12 month low of $35.80 and a 12 month high of $170.47. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05. The firm has a market cap of $16.10 billion, a PE ratio of -7.19 and a beta of 1.58. The stock has a 50 day moving average of $48.26 and a 200-day moving average of $83.22.

Moderna (NASDAQ:MRNA) last released its earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, beating the consensus estimate of ($1.89) by $1.92. The firm had revenue of $1.90 billion during the quarter, compared to analysts’ expectations of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The business’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.39) EPS. On average, equities analysts predict that Moderna, Inc. will post -9.3 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the stock. Oppenheimer downgraded shares of Moderna from an “outperform” rating to a “market perform” rating in a research note on Friday, September 13th. TD Cowen dropped their target price on Moderna from $70.00 to $60.00 and set a “hold” rating on the stock in a research report on Friday, September 13th. Berenberg Bank assumed coverage on Moderna in a report on Tuesday, November 19th. They set a “hold” rating and a $42.00 price target for the company. HSBC upgraded Moderna from a “hold” rating to a “buy” rating and set a $58.00 price objective on the stock in a report on Monday, November 18th. Finally, Bank of America reiterated an “underperform” rating and issued a $41.00 target price on shares of Moderna in a research note on Tuesday, December 10th. Four research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $79.50.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.